MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 49 filers reported holding MEREO BIOPHARMA GROUP PLC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $101,910 | -51.0% | 79,000 | -49.9% | 0.00% | – |
Q2 2023 | $208,164 | -0.7% | 157,700 | -46.8% | 0.00% | – |
Q1 2023 | $209,617 | -6.0% | 296,530 | -0.2% | 0.00% | – |
Q4 2022 | $222,922 | -17.7% | 297,230 | -5.6% | 0.00% | – |
Q3 2022 | $271,000 | -24.7% | 314,760 | -2.1% | 0.00% | – |
Q2 2022 | $360,000 | -3.0% | 321,660 | -2.8% | 0.00% | – |
Q1 2022 | $371,000 | -30.3% | 330,900 | -0.4% | 0.00% | – |
Q4 2021 | $532,000 | -35.3% | 332,200 | -2.2% | 0.00% | -100.0% |
Q3 2021 | $822,000 | -47.0% | 339,600 | -30.5% | 0.00% | 0.0% |
Q2 2021 | $1,550,000 | -5.9% | 488,938 | -0.0% | 0.00% | 0.0% |
Q1 2021 | $1,648,000 | -5.9% | 489,100 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $1,751,000 | +36.7% | 489,100 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $1,281,000 | -14.4% | 489,100 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $1,497,000 | +167.3% | 489,100 | -10.0% | 0.00% | 0.0% |
Q1 2020 | $560,000 | -71.6% | 543,375 | -9.7% | 0.00% | 0.0% |
Q4 2019 | $1,974,000 | -0.4% | 601,762 | -11.9% | 0.00% | -50.0% |
Q3 2019 | $1,982,000 | +18.6% | 683,356 | -1.8% | 0.00% | +100.0% |
Q2 2019 | $1,671,000 | – | 696,110 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 523,382 | $1,518,000 | 0.16% |
Birchview Capital, LP | 77,570 | $231,000 | 0.15% |
CSS LLC/IL | 78,207 | $233,000 | 0.02% |
Perceptive Advisors | 179,419 | $534,000 | 0.01% |
PRIMECAP MANAGEMENT CO/CA/ | 683,356 | $1,982,000 | 0.00% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 15,961 | $46,000 | 0.00% |
Tower Research Capital LLC (TRC) | 1,738 | $5,000 | 0.00% |
Renaissance Technologies | 166,123 | $495,000 | 0.00% |
UBS Group AG | 1,124 | $3,000 | 0.00% |
BANK OF AMERICA CORP /DE/ | 12,104 | $36,000 | 0.00% |